The American health authorities proposed, Tuesday, April 13, 2021, the suspension for a few days, for more security, of the COVID-19 vaccine of Johnson & Johnson, the time to analyze in detail six cases of atypical and severe blood clots in people who received this vaccine. Since then, one of the patients has died.
Six women, aged 18 to 48, all presented coagulation disorders during the three weeks following vaccination. A woman died and another was hospitalized in critical condition.
In a joint press release, the disease control and prevention centers (CDC) and the American drug authority (FDA) recommend “a break in the use of this vaccine, in measure of caution”, by the fact that the in -depth analyzes of the reported cases are completed.
“At present, these undesirable effects seem extremely rare”, with six cases identified on more than 6.8 million doses of the J & J vaccine already administered in the United States, but the safety of vaccines is “the absolute priority” of the federal government, underline the two agencies.
The Minister of Health, Faouzi Mehdi had announced, on April 8, that the Tunisian State granted its authorization to this vaccine and that Tunisia should receive 1.5 million doses, within the framework of the initiative of the African Union.
The Janssen vaccine by Johnson & Johnson against COVVI-19 is a single dose and has been developed from adenovirus. It is deemed to be very effective in the severe forms of the disease (more than 76%) including on South African and Brazilian variants.
From a logistical point of view, Johnson & Johnson’s vaccine has a significant advantage, the fact that it requires only one injection.
